Bayer initiates Phase II study with first-in-class anti-alpha2 antiplasmin antibody in patients with deep vein thrombosis
Bayer announced today the start of a Phase II clinical trial (SIRIUS study) with BAY3018250, an investigational first-in-class anti-alpha2 antiplasmin (anti-α2ap) antibody in patients with deep vein thrombosis (DVT).
- Bayer announced today the start of a Phase II clinical trial (SIRIUS study) with BAY3018250, an investigational first-in-class anti-alpha2 antiplasmin (anti-α2ap) antibody in patients with deep vein thrombosis (DVT).
- The results of this study might provide evidence of anti-α2ap antibody’s potential as a treatment option in indications of high medical relevance.
- "We are excited to advance our anti-α2ap antibody to the next stage of clinical development in patients with deep vein thrombosis,” said Christian Rommel, Member of the Executive Committee of Bayer AG's Pharmaceuticals Division and Head of Research and Development.
- Following the successful first-in-human trial, the goal of the randomized, double-blind, placebo-controlled, multi-center Phase II study (SIRIUS study) is to assess the efficacy and safety of BAY3018250 in patients with symptomatic proximal deep vein thrombosis.